Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iobenguane I-123 - GE Healthcare

Drug Profile

Iobenguane I-123 - GE Healthcare

Alternative Names: 123I-Iobenguane; 123I-mIBG; 3-iodobenzylguanidine I-123; AdreView; Iobenguane I123 Injection; Metaiodobenzylguanidine I-123 - GE Healthcare

Latest Information Update: 07 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GE Healthcare
  • Developer GE Healthcare; University of Ottawa Heart Institute
  • Class Antineoplastics; Guanidines; Imaging agents; Iodobenzenes; Radiopharmaceutical diagnostics; Small molecules; Sulfates
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Neuroendocrine tumours
  • Registered Neuroblastoma

Most Recent Events

  • 11 Apr 2018 GE Healthcare terminates a phase III trial for Heart failure (Diagnosis) in USA, Canada, France, Italy, Netherlands, Poland, Hungary, Spain, Czech Republic, Germany and Denmark due to lower rate of recruitment of patients (NCT02656329)
  • 01 Jan 2016 GE Healthcare initiates enrolment in a phase-III trial for Heart failure (Diagnosis) in USA (IV) (NCT02656329)
  • 01 Dec 2013 Phase-III clinical trials for Heart failure (Diagnosis) in Canada (IV) (NCT02043522)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top